The company is focused on developing and commercializing hospital pharmaceuticals that address areas of high unmet medical need. Its lead asset, ST10-021, is undergoing global pivotal Phase III studies for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and subsequently chronic kidney disease. Shield Therapeutics has two operating segments based on key products: Feraccru, a novel oral treatment for iron deficiency anemia in patients, and PT20, used to treat hyperphosphatemia. Feraccru is commercially available and generates the maximum revenue for the company.